Hocakrotenalnci-C02959 en es it fr

Hocakrotenalnci-C02959 Brand names, Hocakrotenalnci-C02959 Analogs

Hocakrotenalnci-C02959 Brand Names Mixture

  • No information avaliable

Hocakrotenalnci-C02959 Chemical_Formula


Hocakrotenalnci-C02959 RX_link


Hocakrotenalnci-C02959 fda sheet

Hocakrotenalnci-C02959 msds (material safety sheet)

Hocakrotenalnci-C02959 MSDS

Hocakrotenalnci-C02959 Synthesis Reference

No information avaliable

Hocakrotenalnci-C02959 Molecular Weight

296.543 g/mol

Hocakrotenalnci-C02959 Melting Point

71.5 oC

Hocakrotenalnci-C02959 H2O Solubility

4.09 mg/L

Hocakrotenalnci-C02959 State


Hocakrotenalnci-C02959 LogP


Hocakrotenalnci-C02959 Dosage Forms


Hocakrotenalnci-C02959 Indication

For the treatment and management of chronic alcoholism

Hocakrotenalnci-C02959 Pharmacology

Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism of the same amount of alcohol alone. Accumulation of acetaldehyde in the blood produces a complex of highly unpleasant symptoms referred to hereinafter as the disulfiram-alcohol reaction. This reaction, which is proportional to the dosage of both disulfiram and alcohol, will persist as long as alcohol is being metabolized. Disulfiram does not appear to influence the rate of alcohol elimination from the body. Prolonged administration of disulfiram does not produce tolerance; the longer a patient remains on therapy, the more exquisitely sensitive he becomes to alcohol.

Hocakrotenalnci-C02959 Absorption

Disulfiram is absorbed slowly from the gastrointestinal tract (80 to 90% of oral dose).

Hocakrotenalnci-C02959 side effects and Toxicity

LD50=8.6g/kg (orally in rats). Symptoms of overdose include irritation, slight drowsiness, unpleasant taste, mild GI disturbances, and orthostatic hypotension.

Hocakrotenalnci-C02959 Patient Information

No information avaliable

Hocakrotenalnci-C02959 Organisms Affected

Humans and other mammals